Table 1.
Antihyperglycemic efficacy of treatment with canagliflozin 100 mg and 300 mg in T2DM - change to HbA1c levels in monotherapy, dual combination therapy, triple combination therapy, and in combination with insulin: examples from placebo-controlled and active-controlled Phase III trials
| Study | Monotherapy CANA vs PBO34 | Dual therapy MET + CANA vs MET + GLIM28 | Dual therapy MET + CANA vs MET + SITA30 | Triple therapy MET + SU + CANA vs MET + SU + SITA32 | Combination with insulina Insulina + CANA vs Insulina + PBO38 | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
|
|
|
|
||||||||||
| Observation term | 26 weeks | 52 weeks | 52 weeks | 52 weeks | 52 weeks | |||||||||
|
|
|
|
|
|
||||||||||
| Treatment groups | PBO | CANA100 mg | CANA 300 mg | GLIM (titrated) | CANA 100 mg | CANA 300 mg | SITA 100 mg | CANA 100 mg | CANA 300 mg | SITA 100 mg | CANA 300 mg | PBO | CANA 100 mg | CANA 300 mg |
| HbAk (%): baseline (average) | 8.0 | 8.1 | 8.0 | 7.8 | 7.8 | 7.8 | 7.9 | 7.9 | 8.0 | 8.1 | 8.1 | 8.2 | 8.3 | 8.3 |
| HbAk (%): change from baseline (adjusted average) | +0.14 | −0.77 P<0.00l vs PBO |
−1.03 P<0.00l vs PBO |
−0.81 | −0.82 | −0.93 | −0.73 | −0.73 | −0.88 | −0.66 | −1.03 | +0.13 | −0.58 | −0.68 |
Notes:
a
With or without other OADs. Bold data indicate change from baseline.
Abbreviations: T2DM, type 2 diabetes mellitus; CANA, canagliflozin; PBO, placebo; MET, metformin; GLIM, glimepiride; SITA, sitagliptin; SU, sulfonylurea; OAD, oral antidiabetic.